6553 26 archive 109 disk0/00/00/65/53 2008-06-11 03:56:10 2008-07-18 11:00:03 2008-07-16 17:26:42 article show changhai.ding@utas.edu.au Ding C chding@utas.edu.au Xu J Li J pub 320503 920211 730304 restricted Changhai Ding For Derek - checked- Doi info on page incorrect doi:10.1186/cd-899624 Thomson Scientific Journals Checked S/RoMEO - Journal: Current Opinion in Investigational Drugs (ISSN: 1472-4472) Publisher: Pharma Press Ltd Have not restricted Sorry, no publisher copyright information found in the SHERPA/RoMEO list. ABT-874, a fully human mAb that blocks the binding of IL-12 and IL-23 to their shared IL-12 receptor beta1, is currently being developed by Abbott Laboratories for the potential treatment of Crohn's disease and psoriasis. The compound is currently in phase III clinical trials for psoriasis and phase II trials for Crohn's disease. ABT-87 was previously being developed for the potential treatment of multiple sclerosis; however, by May 2007, development for this indication was discontinued. 2008-05 published Current Opinion in Investigational Drugs 9 5 515-522 TRUE 1472-4472 http://www.biomedcentral.com/1472-4472/9/515 5394 5 6553 1 application/pdf ABT-874 en staffonly cc_utas

ABT-874.pdf

ABT-874.pdf 370780 http://eprints.utas.edu.au/6553/1/ABT-874.pdf